Stocks and InvestingStocks and Investing
Thu, November 3, 2022
Wed, November 2, 2022

Matthew Biegler Downgraded (BPMC) to Hold on, Nov 2nd, 2022


Published on 2024-10-27 23:50:43 - WOPRAI, Matthew Biegler
  Print publication without navigation


Matthew Biegler of Oppenheimer, Downgraded "Blueprint Medicines Corporation" (BPMC) to Hold on, Nov 2nd, 2022.

Matthew has made no other calls on BPMC in the last 4 months.



There are 6 other peers that have a rating on BPMC. Out of the 6 peers that are also analyzing BPMC, 0 agree with Matthew's Rating of Hold.



These are the ratings of the 6 analyists that currently disagree with Matthew


  • Zhiqiang Shu of "Berenberg" Initiated at Strong Buy and Held Target at $90 on, Wednesday, September 14th, 2022
  • Eun Yang of "Jefferies" Maintained at Strong Buy with Increased Target to $84 on, Monday, August 22nd, 2022
  • Bradley Canino of "Stifel" Maintained at Strong Buy with Increased Target to $100 on, Thursday, August 18th, 2022
  • Derek Archila of "Wells Fargo" Maintained at Sell with Increased Target to $41 on, Wednesday, August 17th, 2022
  • Dane Leone of "Raymond James" Maintained at Strong Buy with Decreased Target to $115 on, Wednesday, August 3rd, 2022
  • Terence Flynn of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $143 on, Wednesday, August 3rd, 2022